Roche Considers Moving Two Drugs Into Phase III, Drops Early-Stage Alzheimer’s Compound In Strong 3^rd Quarter

Roche is moving into Phase III with a Lucentis successor, lampalizumab, in ophthalmology, but has dropped development of a Phase I BACE inhibitor for Alzheimer’s disease, the company announced during a third-quarter earnings update, which highlighted pipeline tweaks amid comparatively strong product sales.